Abstract
Two prespecified analyses of the DECLARE–TIMI 58 trial show that in patients with type 2 diabetes mellitus, dapagliflozin has greater cardiovascular benefit in those with heart failure with reduced ejection fraction at baseline and in those with prior myocardial infarction
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
